N2'-deacetyl-N2'-[3-[[1-[[4-[[(2,5-dioxo-1-pyrrolidinyl)oxy]carbonyl]cyclohexyl]methyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]-maytansine
DM1-SMCC is a cleavable linker-based antibody-drug conjugate (ADC) containing the maytansinoid DM1 and the crosslinker SMCC.1,2 ADCs target specific cell populations to induce a selective response, such as cell death in cancer cells. DM1-SMCC conjugated to an anti-CD70 antibody has been used to study the transport of the ADC catabolites into the cell cytoplasm of 786-0 renal cell carcinoma cells.
1.Luo, Q., Chung, H.H., Borths, C., et al.Structural characterization of a monoclonal antibody-maytansinoid immunoconjugateAnal. Chem.88(1)695-702(2016)
2.Hamblett, K.J., Jacob, A.P., Gurgel, J.L., et al.SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lusosome to the cytoplasmCancer Res.75(24)5329-5340(2015)
